NCT06558838View on ClinicalTrials.gov

Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Herpes Simplex Oral
Interventions
DRUG

acyclovir-penciclovir cream

Patients will treat their cold sore with active study drug based upon their randomization

DRUG

Abreva

Patients will treat their cold sore with Abreva based upon their randomization

Trial Locations (1)

84107

University of Utah MidValley Dermatology, Murray

All Listed Sponsors
lead

University of Utah

OTHER

NCT06558838 - Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions | Biotech Hunter | Biotech Hunter